Nicholas Hoffman & Company, Llc. Biogen Inc. Transaction History

Nicholas Hoffman & Company, Llc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$187.54 - $223.02 $191,478 - $227,703	-1,021 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$193.77 - $244.14 $10,269 - $12,939	-53 Reduced 4.93%	1,021 $215,000
Q4 2021 Feb 10, 2022	BUY	$223.92 - $287.77 $11,867 - $15,251	53 Added 5.19%	1,074 $258,000
Q3 2021 Nov 04, 2021	SELL	$282.99 - $369.05 $9,904 - $12,916	-35 Reduced 3.31%	1,021 $289,000
Q2 2021 Aug 10, 2021	SELL	$259.0 - $414.71 $3,367 - $5,391	-13 Reduced 1.22%	1,056 $366,000
Q1 2021 May 11, 2021	BUY	$242.95 - $284.63 $7,531 - $8,823	31 Added 2.99%	1,069 $299,000
Q4 2020 Feb 11, 2021	BUY	$236.26 - $355.63 $245,237 - $369,143	1,038 New	1,038 $254,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Nicholas Hoffman & Company, Llc., based on Form 13F filings with the SEC.

Stay updated on Nicholas Hoffman & Company, Llc. with notifications on news.